Fact check

Is compounded semaglutide just a generic?

No. “Generic” and “compounded” describe different things. One is an FDA-approved copy. The other is a medicine made by a pharmacy or doctor under a separate set of rules.

The rules on this topic change often, so each fact here says when it was true.

Torn black and white paper layers aligning around one precise circular opening
Words that sound alike can mean the FDA checked one product and not the other.
Myth

If the ingredient is semaglutide, the products are basically the same.

Short answer

As of September 2026, the US market had no FDA-approved generic semaglutide. A compounded preparation was not an approved generic, even when a site described it that way.

Three labels, three different meanings

Start with the label, then ask for the exact product. The ingredient name alone does not show what was reviewed or who made it.

Approved brand medicine

As of September 2026, the approved semaglutide brands were Ozempic, Wegovy, and Rybelsus. FDA reviewed each one for named forms and uses.

Generic semaglutide

As of September 2026, one company’s generic had only tentative approval. That meant the FDA found the application acceptable, but the medicine could not be sold yet. No semaglutide generic had final approval for the US market.

Compounded semaglutide

A compounded drug is made to order. It is not approved as a finished product. FDA does not check its safety, effect, or quality before sale.

Why the shortage matters

FDA declared the semaglutide injection shortage over on February 21, 2025. During the shortage, pharmacies were allowed to make copies. That extra time ended on April 22, 2025 for regular pharmacies and May 22, 2025 for outsourcing facilities.

An outsourcing facility is a bigger business that makes batches of medicines, often for clinics and hospitals, under its own set of federal rules. That is why its deadline differed.

As of April 1, 2026, the FDA said semaglutide was not on its shortage list. It was also not on the list of ingredients that outsourcing facilities may use. In plain words, the shortage reason for making copies no longer applied.

Does that rule out every compounded use?

No. As of September 2026, compounding itself was not banned. As of that date, federal law limited routine copies of an available approved drug. The law made one exception. The person prescribing could order a changed version when that change made a real medical difference for one particular patient.

As of September 2026, FDA said that adding a vitamin to a similar semaglutide injection could still leave it “essentially a copy.” As of that date, a lower price alone did not count as that kind of medical difference.

See how evidence gets ranked
Annotated reading list

The official trail